Webinar: Using HEOR Methods to Reduce Health Inequalities
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
Webinar: Gene Therapies In Hemophilia
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
(more…)
Webinar: Optimizing Product Launch Market Access strategy and Gross-to-Net Modeling
Join Precision and Akara Group on Thursday, 8/6, 2020 | 12:00 PM EDT – 1:00 PM EDT for a special live, online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.
(more…)
Precision for Medicine Partners with Karyopharm Therapeutics to Initiate New Global Clinical Trial to Treat Patients with COVID-19
PRECISION FOR MEDICINE PARTNERS WITH KARYOPHARM THERAPEUTICS TO INITIATE NEW GLOBAL CLINICAL TRIAL TO TREAT PATIENTS WITH COVID-19
— First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections
— Precision for Medicine Responsible for Clinical Trial Management in Europe
BUDAPEST, April 22, 2020 – Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.